HTA Digital Shifts & Pricing Pressures

MarcusWelcome to the Access Brief — your daily briefing on what's moving in HEOR, HTA, and market access. I'm Marcus, and it's great to have you with us today.

SaraAnd I'm Sara. Always good to be here — and I'll say, today's topics are hitting at the heart of where the field is evolving right now.

MarcusSame here. We're looking at HTA data integration challenges with digital health — why interoperability is becoming make-or-break. Then emerging market pricing strategies for innovative therapies — the pressure points there are intensifying. Plus blockchain applications in real-world evidence and environmental sustainability metrics in value assessments.

SaraThat second one is particularly timely — the budget impact calculations for emerging markets are becoming increasingly complex as payer expectations shift.

MarcusExactly. Let's get into it.

MarcusStarting with HTA data integration challenges with digital health. The fragmentation between clinical trial data and real-world digital health data is creating significant bottlenecks in submissions.

SaraAbsolutely. What strikes me is how HTA bodies are struggling with data standardization across different digital platforms. The heterogeneity in wearables and apps makes consistent endpoint measurement nearly impossible.

MarcusThat's fair, though I think payers would see it differently — the real issue isn't just standardization but the sheer volume of unstructured data that requires novel analytical approaches.

SaraI'd push back slightly on that — the methodological challenges in validating digital endpoints are the primary barrier. HTA agencies lack the infrastructure to process these novel data types at scale.

MarcusThat connects to something I keep coming back to: the opportunity cost of not integrating digital health data properly. It delays patient access to potentially transformative interventions.

SaraExactly, and from the payer side, the risk of misinterpreting digital endpoints could lead to inappropriate coverage decisions. The evidence generation gap is widening.

MarcusThe part that gives me pause is how this fragmentation affects comparative effectiveness research. We need harmonized frameworks yesterday.

SaraAgreed. This is one of those stories where the technology is outpacing the evidence infrastructure.

MarcusShifting to emerging market pricing strategies for innovative therapies. The value demonstration requirements are becoming more stringent, creating a significant access barrier.

SaraWhat's striking here is the divergence between willingness-to-pay thresholds and actual budget constraints. Emerging markets are demanding innovative pricing models but lack the fiscal flexibility to implement them.

MarcusThat's one read — I'd frame it slightly differently as a market segmentation challenge. Companies need differentiated value propositions that account for local health system priorities.

SaraI wonder if that's the full picture though? The historical precedent shows that purely commercial models fail when local health economics aren't addressed. The budget impact question there remains unresolved.

MarcusThe part that gives me pause is how this affects R&D allocation decisions. If emerging markets can't demonstrate viable pathways, innovation may bypass those populations entirely.

SaraExactly, and from the payer side, the opportunity cost of high-priced innovative therapies is unsustainable when basic care needs are unmet. This tension requires creative solutions.

MarcusRight, and what's interesting is how some companies are using tiered pricing with outcome-based agreements. But the implementation hurdles are substantial.

SaraThis is one of those stories where the theory and practice of value-based pricing are colliding in emerging markets.

MarcusNow blockchain applications in real-world evidence. The potential for tamper-proof data trails could revolutionize post-marketing surveillance, but adoption remains limited.

SaraWhat strikes me about that is the governance vacuum. Without standardized protocols for blockchain-secured RWE, we're creating more data silos than solutions.

MarcusThat's fair, though I think payers would see it differently — the primary barrier is the lack of regulatory acceptance for blockchain-derived evidence in HTA submissions.

SaraI'd push back slightly on that — the real challenge is the technical complexity and integration costs. Healthcare systems aren't equipped to implement this infrastructure at scale.

MarcusThat connects to something I keep coming back to: the trust deficit between industry and HTA bodies. Blockchain could address that if we develop common standards.

SaraExactly, and from the payer side, the risk of vendor lock-in with proprietary blockchain solutions is significant. We need open frameworks.

MarcusThe part that gives me pause is how this affects decentralized clinical trials. Blockchain could enable truly global RWE networks, but the methodological validation is lagging.

SaraAgreed. This is one of those stories where the technology promise exceeds current operational reality.

MarcusFinally, environmental sustainability metrics in value assessments. Some HTA bodies are beginning to incorporate carbon footprint calculations into their frameworks.

SaraWhat's striking here is the methodological inconsistency. There's no standardized approach for quantifying environmental impact in health economic models.

MarcusThat's one read — I'd frame it slightly differently as an inevitable evolution of value frameworks. Sustainability is becoming a core component of patient value.

SaraI wonder if that's the full picture though? The budget impact of implementing these assessments could divert resources from direct patient benefits. The opportunity cost is real.

MarcusThe part that gives me pause is how this affects cross-jurisdictional submissions. Different HTA bodies will prioritize sustainability differently, creating new access barriers.

SaraExactly, and from the payer side, we're not equipped to validate these claims. The evidence base is nascent and lacks transparency.

MarcusRight, and what's interesting is how this intersects with the digital health discussion. Blockchain could enable sustainability tracking through the supply chain.

SaraThis is one of those stories where the ethical imperative is outpacing the methodological readiness.

SaraA lot to think about today. I'll be watching how HTA bodies develop practical frameworks for digital health data integration and sustainability metrics.

MarcusSame — and for me the thread running through today is the growing tension between technological innovation and evidence infrastructure. The gaps are widening.

SaraThanks so much for listening — really glad you're here with us.

MarcusWe'll be back tomorrow. Show notes and transcripts at outcomes-analytica.no. See you then.

SaraThanks for listening — see you tomorrow.

MarcusBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.